TMEM106B analysis in diverse cohorts suggests no association with Parkinson's disease risk
- 1McGill University
Abstract
Recent evidence suggests that TMEM106B expression is reduced in the brains of patients with Parkinsons disease (PD). However, an association between rare genetic variants in TMEM106B and PD risk has not been previously established. In this work, we investigated the association between rare TMEM106B variants and PD risk. We leveraged whole-genome sequencing data from 22,010 cases and 40,550 controls across diverse ancestries from the Global Parkinsons Genetics Program (GP2), the Accelerating Medicines Partnership in Parkinsons Disease (AMP-PD), and the UK Biobank (UKBB). A total of 4,581 unique rare variants were identified across all groups. We found no evidence that rare coding variants in TMEM106B were associated with PD risk, either individually or through cumulative burden. These findings suggest that rare variation in TMEM106B does not play a major role in PD susceptibility across the populations studied.
Related
- Multi-omics profiling suggests deep brain stimulation-associated expansion of CLIC3+ NK cells attenuates neuroinflammation in Parkinson's disease
- Illicit opioids, methamphetamine/amphetamine, and cocaine use are associated with loss of housing and delay with becoming rehoused across seven diverse cohorts with and without HIV in the United States and Canada
- Association between early postoperative acetaminophen exposure and acute kidney injury across surgical cohorts: a retrospective analysis of the MIMIC-IV database
- Meaningful digital mobility outcomes for people with Parkinson's disease: Insights grounded in diverse lived experience.
- The impact of self-rated health on the Parkinson’s disease-disability association: evidence from CHARLS
BibTeX
@misc{chaparrosolano2026tmem106b,
title = {{TMEM106B analysis in diverse cohorts suggests no association with Parkinson's disease risk}},
author = {H. M. Chaparro-Solano and S. Kanagasingam and Z. Gan-Or and K. Senkevich and the Global Parkinson's Genetic Program (GP2)},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.28.26363833},
url = {https://www.medrxiv.org/content/10.64898/2026.09.28.26363833v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - TMEM106B analysis in diverse cohorts suggests no association with Parkinson's disease risk
AU - H. M. Chaparro-Solano
AU - S. Kanagasingam
AU - Z. Gan-Or
AU - K. Senkevich
AU - the Global Parkinson's Genetic Program (GP2)
PY - 2026
DA - 2026/09/28
PB - medRxiv
DO - 10.64898/2026.09.28.26363833
UR - https://www.medrxiv.org/content/10.64898/2026.09.28.26363833v1
AB - Recent evidence suggests that TMEM106B expression is reduced in the brains of patients with Parkinsons disease (PD). However, an association between rare genetic variants in TMEM106B and PD risk has not been previously established. In this work, we investigated the association between rare TMEM106B variants and PD risk. We leveraged whole-genome sequencing data from 22,010 cases and 40,550 controls across diverse ancestries from the Global Parkinsons Genetics Program (GP2), the Accelerating Medicines Partnership in Parkinsons Disease (AMP-PD), and the UK Biobank (UKBB). A total of 4,581 unique rare variants were identified across all groups. We found no evidence that rare coding variants in TMEM106B were associated with PD risk, either individually or through cumulative burden. These findings suggest that rare variation in TMEM106B does not play a major role in PD susceptibility across the populations studied.
ER -